Menu Back toWhat is the Breakthrough Risk Communications and Assessing Safety After Early Access to Pharmaceuticals?

DIA 2021 Global Annual Meeting

What is the Breakthrough Risk Communications and Assessing Safety After Early Access to Pharmaceuticals?

Session Chair(s)

Rie Matsui, RPh

Rie Matsui, RPh

  • Senior Director, Regional Labeling Head for APAC
  • Pfizer R&D Japan, Japan
The principle of patient-centric labeling and assessing safety will be discussed to seek an opportunity for international harmonization for implementing earlier access to medicines as the breakthrough risk communication.
Learning Objective : Describe the current challenges for risk communication to patients across regions; Identify the future breakthrough risk communication to patients and principle of patient-centric labeling; Discuss how to assess safety after early access to Pharmaceuticals; Discuss how to measure the effectiveness of risk communication/patient-centric labeling.

Speaker(s)

Gerald J. Dal Pan, MD, MHS

Postmarket Safety Label Changes: Relationship to Development Pathways

Gerald J. Dal Pan, MD, MHS

  • Director, Office of Surveillance and Epidemiology, CDER
  • FDA, United States
Junko Sato, PhD

Communication with Public/Patients to Promote Appropriate use of Medical Products in Japan

Junko Sato, PhD

  • Director, Office of International Programs
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Meredith Smith, PhD, MPA, FISPE

Patient Labeling: Current State and Future Directions

Meredith Smith, PhD, MPA, FISPE

  • Senior Director, Implementation Science Pillar Lead
  • Evidera, Inc, United States